What analysts say:
- Buy, sell, or hold?: Half of analysts think investors should stand pat on UGI while the remaining half rate the stock as a buy. Analysts like UGI better than competitor Vectren overall. Zero out of six analysts rate Vectren a buy compared to one of two for UGI. Analysts' rating of UGI has stayed constant from three months prior.
- Revenue Forecasts: On average, analysts predict $2.76 billion in revenue this quarter. That would represent a rise of 26.6% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $1.24 per share. Estimates range from $1.23 to $1.25.
What our community says:
CAPS All-Stars are strongly supporting the stock, with 95.7% giving it an "outperform" rating. Most of the community concurs with the All-Stars, with 94.9% awarding it a rating of "outperform." UGI has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
A year-over-year revenue decrease last quarter snaps a streak of three consecutive quarters of revenue increases.
For all our UGI-specific analysis, including earnings and beyond, add UGI to My Watchlist.
Motley Fool newsletter services have recommended buying shares of UGI. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.